Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The building is named after Angelika ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with limited treatment options.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

In the future, around one third of the new products at Boehringer Ingelheim will come from oncology.” Newest technologies and laboratories allow scientists to faster achieve their goal to develop ...

Report on how AI is redefining market landscape - The Global Gastrointestinal Diseases Therapeutics Market size is es ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...

This year’s honorees, Boehringer Ingelheim and GSK, have set new standards in sustainable manufacturing. Boehringer Ingelheim’s team created a highly efficient 3-step synthesis for Spiroketone CD 7659 ...

The global Cattle & Porcine/Swine Reproductive Diseases market is expected to grow to USD 975.8 Million by 2029, up from USD ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.